HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company developing fusion Immunotherapeutics for cancer, autoimmune disease, and age-related disorders, announced the pricing of a private placement valued at approximately $4.0 million.
Offering Details
The financing involves 2,846,975 units priced at $1.405 per unit, each consisting of one share of common stock (or a pre-funded warrant) and one warrant to purchase common stock. The warrant are exercisable immediately at $1.28 per share and will expire five and a half years from issuance.
The closing of the offering is expected on or about May 21, 2025, subjected to customary closing conditions. E.F. Hutton & Co. LLC is acting as the sole placement agent.
Use of Proceeds
HCW Biologics said net proceeds will support ongoing clinical trials of HCW9302, advance IND-enabling studies for its T-Cell Engager, HCW11-018b, and its second-generation immune checkpoint inhibitor, HCW11-040, as well as fund general corporate purposes and debt settlements.
Regulatory Commitments
The company also entered into a registration rights agreement with investors, committing to file a Form S-1 within 60 days of the closing to cover resale of purchased shares and warrant-related shares.
The company implemented a 1-for-40 reverse stock split on April 7, 2025.
HCWB is currently trading at $2.15, down 11.41%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.